LHHealthcare · Diagnostics & ResearchThe 18 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $353 — +13.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.0% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Sept 2026 | Truist Securities | Maintains | Buy | $350 → $365 |
| 11 Sept 2026 | Barclays | Maintains | Equal-Weight | — |
| 11 Sept 2026 | Barclays | Maintains | Equal-Weight | $320 → $330 |
| 11 Sept 2026 | UBS | Maintains | Buy | $361 → $380 |
| 11 Sept 2026 | UBS | Maintains | Buy | — |
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | $300 → $309 |
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | $330 → $360 |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 31 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 31 July 2026 | Barclays | Maintains | Equal-Weight | $290 → $320 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | $308 → $338 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 31 July 2026 | Truist Securities | Maintains | Buy | $320 → $350 |
| 31 July 2026 | Truist Securities | Maintains | Buy | — |
| 13 July 2026 | B of A Securities | Maintains | Buy | — |
| 13 July 2026 | B of A Securities | Maintains | Buy | $300 → $320 |
| 13 July 2026 | Baird | Maintains | Outperform | $335 → $338 |
| 13 July 2026 | Baird | Maintains | Outperform | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Labcorp Holdings, Inc. returned +12.7% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 55% of US stocks
Cheaper than 32% of US stocks
Cheaper than 26% of US stocks
Higher than 41% of US stocks
Higher than 63% of US stocks
Higher than 34% of US stocks
Higher than 68% of US stocks
Higher than 64% of US stocks
Higher than 67% of US stocks
Higher than 79% of US stocks
Higher than 69% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Labcorp Holdings, Inc. has a market value of $25.0B and an enterprise value of $31.7B.
Revenue in the twelve months to 30 June 2026: $14.3B. The latest quarter grew 5.8% year on year.
Net income over the same four quarters: $1.0B, a 7.0% net margin.
Diluted earnings per share, trailing twelve months: $12.09.
Free cash flow in the twelve months to 30 June 2026: $1.2B, after $483.2M of capital spending.
Labcorp Holdings, Inc. spent $701.8M on share buybacks and $239.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 25.7×; forward P/E: 15.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.92%, paying out 24% of earnings.
Labcorp Holdings, Inc. employs 71,000 people — $202K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research’s article explains that Zacks Style Scores help investors identify stocks rated highly according to their investing style, framing Labcorp Holdings as a strong value stock.
Why it matters — LH watchers may care because the article presents a value-oriented perspective on the company using Zacks’ stock-rating framework.
Labcorp Holdings Inc. announced it will report its third quarter 2026 financial results on October 28, 2026. The company made this announcement via a press release from Burlington, N.C.
Why it matters — Investors and analysts following Labcorp will be watching for the company's Q3 2026 performance when the results are released on that date.
Zacks Investment Research discusses Labcorp's expansion of specialty testing and consumer services through acquisitions, partnerships, and AI initiatives, while noting that reimbursement and cost risks remain.
Why it matters — Labcorp watchers would monitor how the company's growth strategy in specialty testing and consumer services balances against ongoing reimbursement and cost pressures.
Labcorp's shares fell sharply after CMS released preliminary 2027 lab-payment rates that align Medicare rates closer to private insurers and target $1 billion in annual savings. The article contends the selloff is overdone, noting the proposed cuts are capped at 15% and final rates are still pending.
Why it matters — A shareholder would care because the CMS rate proposal is the main driver of the recent share decline, and the article argues the market's reaction may overstate the impact on Labcorp's Medicare Clinical Laboratory Fee Schedule revenue.
Labcorp reported robust Q2 results and resilient demand for diagnostics, despite upcoming Medicare rate cuts. The company outperformed both the S&P 500 and healthcare peers for the year to date, with strong technical support and positive operating margins.
Why it matters — For Labcorp watchers, revenue durability, new test launches, and a diversified biopharma segment point to a stronger growth and risk profile even amid regulatory headwinds such as Medicare rate cuts.
The 18 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $353, with estimates ranging from $293 to $385. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 86 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Labcorp Holdings, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +13.0% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 86 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $293 to $385 over the next 12 months.
Labcorp Holdings, Inc. returned +12.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Here's Why Labcorp Holdings (LH) is a Strong Value Stock". Zacks Investment Research’s article explains that Zacks Style Scores help investors identify stocks rated highly according to their investing style, framing Labcorp Holdings as a strong value stock.
Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support. Its Diagnostics Laboratories segment covers testing in areas such as oncology, women’s health, autoimmune disease, and neurology, while its Biopharma Laboratory Services segment supports pharmaceutical and biotech clients with laboratory capabilities for clinical trials and development programs. The company plays a key role in healthcare by helping customers generate data used in diagnosis, treatment decisions, and biomedical research.
CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com
